BeiGene – Talk Bio

Advancements in BTK Inhibitors for Chronic Lymphocytic Leukemia: A Comparative Analysis of AstraZeneca, Eli Lilly, and BeiGene Therapies

4 months ago talkbio0Tagged acalabrutinib, AstraZeneca, BeiGene, Bruton's Tyrosine Kinase Inhibitors [MoA], Chronic Lymphocytic Leukemia, CLL, Continuous therapy, Effectiveness, Eli, Eli Lilly, Fixed-Duration Therapy, ibrutinib, Nemtabrutinib, Pirtobrutinib, Safety, zanubrutinib

BTK inhibitors, Chronic Lymphocytic Leukemia (CLL), AstraZeneca, Eli Lilly, BeiGene, Acalabrutinib, Ibrutinib, Zanubrutinib, Pirtobrutinib, Nemtabrutinib, Fixed-duration therapy, Continuous therapy, Efficacy, Safety

European Commission Approves BeiGene’s TEVIMBRA for First-Line Treatment of Advanced/Metastatic Esophageal Squamous Cell Carcinoma and Gastric or Gastroesophageal Junction Cancer

5 months ago talkbio0Tagged BeiGene, Cancer Therapeutic Procedure, Commission approval, European (ethnic group), first-line, Gastroesophageal Junction Adenocarcinoma, Squamous cell carcinoma of esophagus, Stomach, Tevimbra, tislelizumab

TEVIMBRA, tislelizumab, European Commission approval, first-line treatment, esophageal squamous cell carcinoma, gastric or gastroesophageal junction adenocarcinoma, cancer treatment, BeiGene.

BeiGene Secures Long-Term Protection for BRUKINSA with Patent Settlement Until 2037

5 months ago talkbio0Tagged BeiGene, Brukinsa, BTK gene, Cancer Therapeutic Procedure, competition, exclusivity, Inhibitor, Market, MSN gene, Patent Settlement

BeiGene, BRUKINSA, patent settlement, MSN Pharmaceuticals, generic competition, market exclusivity, BTK inhibitor, cancer treatment

BeiGene Rebrands as BeOne Medicines, Emphasizing Global Unity Against Cancer

5 months ago talkbio0Tagged BeiGene, Changing, Global Oncology, Malignant Neoplasms, Strategic Growth

BeiGene, BeOne Medicines, Global Oncology, Cancer Treatment, Name Change, Strategic Growth

Duality Biotherapeutics Files for Hong Kong IPO, Expanding ADC Therapeutics Portfolio

8 months ago talkbio0Tagged BeiGene, BioNTech, biotherapeutics, Duality, IPO, Kong, Malignant Neoplasms, therapeutic autologous dendritic cells

Duality Biotherapeutics, Hong Kong IPO, ADC Therapeutics, BioNTech, BeiGene, Cancer Treatment

FDA to Reassess Use of PD-1 Inhibitors in Stomach Cancer, Seeking Expert Input on Merck, BMS, and BeiGene Medications

8 months ago talkbio0Tagged BeiGene, BMS, Burning Mouth Syndrome, Gene Expression, inhibitors, Merck, Oncologic, PD-L1, PD-L1, PDCD1 gene, United States Food and Drug Administration

FDA, PD-1 inhibitors, stomach cancer, Merck, BMS, BeiGene, Oncologic Drugs Advisory Committee, PD-L1 expression

BeiGene CEO Eyes Biologics Deals for New US Innovation Center in New Jersey

9 months ago talkbio0Tagged BeiGene, Biological Factors, CEO, deals, innovation, New Jersey

BeiGene, biologics, innovation center, New Jersey, deals, CEO, John Oyler

Brukinsa by BeiGene Secures FDA Approval for Follicular Lymphoma Amid Imbruvica Setbacks

1 year ago talkbio0Tagged Accelerated, Antibodies, Bispecific, Approved, BeiGene, Brukinsa, Chimeric Antigen Receptor T-cells, Clinical Trials, Combined Modality Therapy, competition, Disease Progression, Gazyva, Lymphoma, Follicular, obinutuzumab, ORR, Overall response rate, Rosewood, Toxicity aspects, United States Food and Drug Administration, zanubrutinib

Brukinsa (zanubrutinib), BeiGene, FDA approval, follicular lymphoma, accelerated approval, obinutuzumab (Gazyva) combination therapy, ROSEWOOD trial, overall response rate (ORR), disease progression or unacceptable toxicity, competition with CAR-T cell therapies/ bispecific antibodies

BeiGene Scores Two Major FDA Approvals – Trivimbra for Esophageal Cancer and Brukinsa for Follicular Lymphoma

1 year ago talkbio0Tagged Accelerated Approval, Approved, BeiGene, Brukinsa, Esophageal Neoplasms, Lymphoma, Follicular, obinutuzumab, tislelizumab, Trivimbra, United States Food and Drug Administration, zanubrutinib

BeiGene, Trivimbra (tislelizumab), Esophageal Cancer, Brukinsa (zanubrutinib), Follicular Lymphoma, FDA Approval, Accelerated Approval, Obinutuzumab